FIS heads into Q3 with steady estimates and strong Banking Solutions growth that could fuel another earnings beat.
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.89% and +2.11%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback